Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Mycophenolic Sodium Patent Expiration

Mycophenolic Sodium is Used for preventing organ rejection in patients who have received allogeneic renal transplants. It was first introduced by Novartis Pharmaceuticals Corp in its drug Myfortic on Feb 27, 2004. 12 different companies have introduced drugs containing Mycophenolic Sodium.


Mycophenolic Sodium Patents

Given below is the list of patents protecting Mycophenolic Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Myfortic US6025391 Enteric-coated pharmaceutical compositions of mycophenolate Apr 10, 2017

(Expired)

 Novartis
Myfortic US6172107 Entric-coated pharmaceutical compositions Apr 10, 2017

(Expired)

 Novartis
Myfortic US6306900 Enteric coated pharmaceutical compositions Feb 27, 2018

(Expired)

 Novartis



Mycophenolic Sodium Generics

Several generic applications have been filed for Mycophenolic Sodium. The first generic version for Mycophenolic Sodium was by Apotex Inc and was approved on Aug 21, 2012. And the latest generic version is by Wanbang Biopharmaceuticals Inc and was approved on May 29, 2024.

Given below is the list of companies who have filed for Mycophenolic Sodium generic.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Aug 23, 2017
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Aug 23, 2017


2. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Sep 23, 2021
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Sep 23, 2021


3. AMTA

Amta Labs Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Amta.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Feb 10, 2021
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Feb 10, 2021


4. APOTEX INC

Apotex Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Apotex Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Aug 21, 2012
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Aug 19, 2014


5. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Feb 27, 2024
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Feb 27, 2024


6. BIOCON PHARMA

Biocon Pharma Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Biocon Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Nov 29, 2023
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Nov 29, 2023


7. CONCORD BIOTECH LTD

Concord Biotech Ltd has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Concord Biotech Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Dec 13, 2019
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Dec 13, 2019


8. RK PHARMA

Rk Pharma Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Rk Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Jan 8, 2014
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Jan 8, 2014


9. TEVA PHARMS USA

Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Discontinued ORAL N/A Oct 30, 2014
EQ 360MG BASE tablet, delayed release Discontinued ORAL N/A Oct 30, 2014


10. TWI PHARMS

Twi Pharmaceuticals Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Twi Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB Nov 3, 2021
EQ 360MG BASE tablet, delayed release Prescription ORAL AB Nov 3, 2021


11. WANBANG BIOPHARMS

Wanbang Biopharmaceuticals Inc has filed for 2 different strengths of generic version for Mycophenolic Sodium. Given below are the details of the strengths of this generic introduced by Wanbang Biopharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 180MG BASE tablet, delayed release Prescription ORAL AB May 29, 2024
EQ 360MG BASE tablet, delayed release Prescription ORAL AB May 29, 2024